Eucure Biopharma will receive $5.76M up front, ~$51.84M in development milestones & ~$28.22M in sales milestones along with royalties. The companies collaborated for the clinical development & commercialization of YH008 in Greater China (incl. Mainland China, Hong Kong, Macau & Taiwan)
Eucure Biopharma holds the rights globally to develop & commercialize YH008 outside Greater China. The agreement will accelerate Chipscreen NewWay’s pipeline in the field of Ab drugs & immuno-oncology
YH008 is a bispecific Ab that exerts antagonistic & agonistic activities & showed superior anti-tumor activity over parental mAbs or combination therapy in syngeneic models. Comparing YH008 to benchmark mAbs, both in vivo studies & GLP toxicology studies show improved safety
Ref: Businesswire| Image: Biocytogen
Related News:- Biocytogen Enters into Evaluation and Option Agreement with ADC Therapeutics for Antibody-Based Therapies
